# EDGAR Filing Document

**Accession Number:** 0001445283
**File Stem:** 0000950170-25-089443
**Filing Date:** 2025-6
**Character Count:** 21475
**Document Hash:** ce92fdba48e1bb49bbf7b83b6b08e729
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-089443.hdr.sgml**: 20250624

**ACCESSION NUMBER**: 0000950170-25-089443

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20250623

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250624

**DATE AS OF CHANGE**: 20250624

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** KINETA, INC./DE
- **CENTRAL INDEX KEY:** 0001445283
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37695
- **FILM NUMBER:** 251068913

**BUSINESS ADDRESS:**
- **STREET 1:** 7683 SE 27TH STREET
- **STREET 2:** SUITE 481
- **CITY:** MERCER ISLAND
- **STATE:** WA
- **ZIP:** 98040
- **BUSINESS PHONE:** (206) 378-0400

**MAIL ADDRESS:**
- **STREET 1:** 7683 SE 27TH STREET
- **STREET 2:** SUITE 481
- **CITY:** MERCER ISLAND
- **STATE:** WA
- **ZIP:** 98040

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** YUMANITY THERAPEUTICS, INC.
- **DATE OF NAME CHANGE:** 20201223

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PROTEOSTASIS THERAPEUTICS, INC.
- **DATE OF NAME CHANGE:** 20140813

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PROTEOSTASIS THERAPEUTICS INC
- **DATE OF NAME CHANGE:** 20080916

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM** 8-K

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** June 23, 2025

KINETA, INC.

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| Delaware | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;001-37695 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20-8436652 |
| **(State or other jurisdiction** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(Commission** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(IRS Employer** |
| **of incorporation)** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**File Number)** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Identification No.)** |
| 7683 SE 27th Street**,** Suite 481 |  |  |
| Mercer Island**,** WA |  | 98040 |
| **(Address of principal executive offices)** |  | **(Zip Code)** |

---

**Registrant's telephone number, including area code:** (206) 378-0400

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | | |
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange**<br>**on which registered** |
| Common Stock, par value $0.001 per share | KANT | **OTC Pink Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 5.07** | **Submission of Matters to a Vote of Security Holders.**  |

---

On June 23, 2025, Kineta, Inc. ("Kineta") held its previously announced Special Meeting of Stockholders (the "Special Meeting"). At the Special Meeting, Kineta stockholders voted on the following three proposals, each of which is described in detail in the definitive joint proxy statement/prospectus that was filed on Schedule 14A by Kineta with the Securities and Exchange Commission on May 23, 2025 (the "Definitive Joint Proxy Statement/Prospectus"), in connection with the mergers contemplated by the Agreement and Plan of Merger, dated December 11, 2024 (as amended, the "Merger Agreement"), by and among TuHURA Biosciences, Inc., a Nevada corporation ("TuHURA"), Kineta, Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA, Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA, and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta. A summary of the voting results for the matters proposed at the Special Meeting is set forth below. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Merger Agreement.

There were 13,540,355 shares of Kineta's common stock issued and outstanding as of May 15, 2025, the record date for the Special Meeting (the "Record Date"). At the Special Meeting, the holders of 7,441,449 shares of Kineta's common stock were present or represented by proxy, representing approximately 55% of the total outstanding shares of Kineta's common stock as of the Record Date, which constituted a quorum to conduct business at the Special Meeting. The following are the voting results on proposals considered and voted upon at the Special Meeting, all of which are described in the Definitive Joint Proxy Statement/Prospectus:

***Proposal 1****: Adoption of the Merger Agreement*

At the Special Meeting, Kineta stockholders approved a proposal to adopt the Merger Agreement. The voting results for this proposal were as follows:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **For** | **For** | **Against** | **Against** | **Abstain/Withheld** | **Abstain/Withheld** | **Broker Non-Votes** | **Broker Non-Votes** |
|  | 7,317,175 |  | 45,968 |  | 78,306 |  | - |

---

***Proposal 2****: Advisory (non-binding) vote on Mergers-related compensation for named executive officers*

At the Special Meeting, Kineta stockholders approved, on a non-binding, advisory basis, the Mergers-related compensation that will or may be paid to Kineta's named executive officers in connection with the transactions contemplated by the Merger Agreement. The voting results for this proposal were as follows:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **For** | **For** | **Against** | **Against** | **Abstain/Withheld** | **Abstain/Withheld** | **Broker Non-Votes** | **Broker Non-Votes** |
|  | 6,838,347 |  | 283,607 |  | 319,495 |  | - |

---

***Proposal 3****: Adjournment of the Special Meeting*

The proposal to adjourn the Special Meeting, if necessary or appropriate, (i) to solicit additional proxies if there are insufficient shares of Kineta's common stock represented (either in person or by proxy) and voting to obtain the Company Stockholder Approval or to constitute a quorum necessary to conduct the business of the Special Meeting, (ii) to ensure that any supplement or amendment to the Definitive Joint Proxy Statement/Prospectus is timely provided to Kineta stockholders or (iii) to comply with applicable law, was not necessary and was not acted upon.

**Item 7.01 Regulation FD Disclosure**

On June 23, 2025, TuHURA and Kineta issued a joint press release announcing the voting results of the Special Meeting and the special meeting of TuHURA stockholders. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished, shall not be deemed "filed" for any purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such a filing.

**Additional Information about the Proposed Mergers and Where to Find It** 

This communication may be deemed to be solicitation material with respect to the proposed Mergers between TuHURA and Kineta. In connection with the proposed Mergers, Kineta has filed relevant materials with the SEC, including the Definitive Joint Proxy Statement/Prospectus, which was mailed to Kineta stockholders on or about May 23, 2025. Investors and securityholders of TuHURA and Kineta are urged to read these materials because they contain important information about TuHURA, Kineta and the Mergers. This communication is not a substitute for the Definitive Joint Proxy Statement/Prospectus or any other documents that Kineta may file with the SEC or send to securityholders in connection with the proposed transactions.

Investors and securityholders may obtain free copies of the documents filed with the SEC, once available, on Kineta's website at www.kinetabio.com, on the SEC's website at www.sec.gov or by directing a request to Kineta's Investor Relations at (206) 378-0400.

------

**No Offer or Solicitation**

This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.

**Cautionary Statement Regarding Forward-Looking Statements**

You should carefully consider the foregoing factors and the other risks and uncertainties that affect the businesses of TuHURA and Kineta described in the "Risk Factors" section of their respective Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents filed by either of them from time to time with the SEC, including the Definitive Joint Proxy Statement/Prospectus. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. All forward-looking statements by their nature address matters that involve risks and uncertainties, many of which are beyond TuHURA's and Kineta's control, and are not guarantees of future results. Readers are cautioned not to put undue reliance on forward-looking statements, and TuHURA and Kineta assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law. Neither TuHURA nor Kineta gives any assurance that either TuHURA or Kineta will achieve its expectations.

------

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

(d) Exhibits

---

| | |
|:---|:---|
| Exhibit<br>No. | Description |
| 99.1 | [<u>Joint Press Release of TuHURA and Kineta, dated June 23, 2025.</u>](kant-ex99_1.htm) |
| 104 | Cover Page Interaction Date File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 24, 2025

Kineta, Inc.

---

| | |
|:---|:---|
| By: | /s/ Craig Philips |
| Name: | Craig Philips |
| Title: | President |

---

------

## Exhibit 99.1

**Exhibit 99.1**

---

| | |
|:---|:---|
| ![img118959689_0.jpg](img118959689_0.jpg) | ![img118959689_1.jpg](img118959689_1.jpg) |

---

**TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals**

TAMPA, Fla., and Seattle, Wash., June 23, 2025 — **TuHURA Biosciences, Inc.** (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced with Kineta, Inc. (OTC Pink:KANT) ("Kineta"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, that TuHURA stockholders approved all of the proposals set forth at the Company's Special Meeting of Stockholders held today, June 23, 2025 (the "TuHURA Special Meeting"). The proposals included an increase of the Company's authorized shares to 200 million shares and a proposal to reincorporate the Company in Delaware.

Additionally, Kineta stockholders approved the proposed merger (the "Merger") with TuHURA at Kineta's Special Meeting of Stockholders held today, June 23, 2025 (the "Kineta Special Meeting"). The parties anticipate that the Merger will close as soon as possible following the satisfaction or waiver of any remaining closing conditions.

The final voting results of the TuHURA Special Meeting and the Kineta Special Meeting will be reported in Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission.

**About TuHURA Biosciences, Inc.**

TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common reasons cancer immunotherapies fail to work or stop working in the majority of patients with cancer.

TuHURA's lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda<sup>®</sup> (pembrolizumab) compared to Keytruda<sup>®</sup> plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

In addition to its innate immune agonist product candidates, TuHURA is leveraging its Delta Opioid Receptor technology to develop first-in-class, bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

------

---

| | |
|:---|:---|
| ![img118959689_0.jpg](img118959689_0.jpg) | ![img118959689_1.jpg](img118959689_1.jpg) |

---

For more information, please visit www.tuhurabio.com and connect with TuHURA on Facebook, X, and LinkedIn.

**About Kineta**

Kineta, Inc. (OTC Pink: KANT) is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients' lives. Kineta has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the major challenges with current cancer therapy. Kineta's immuno-oncology pipeline includes KVA12123, a novel VISTA blocking immunotherapy currently in a Phase 1/2 clinical trial in patients with advanced solid tumors, and a preclinical monoclonal antibody targeting CD27. For more information on Kineta, please visit www.kinetabio.com.

Through the combination of unique epitope binding and an optimized IgG1 Fc region, KVA12123 has demonstrated strong tumor growth inhibition as both a monotherapy and in combination with other checkpoint inhibitors in preclinical models. KVA12123 provides a novel approach to address immune suppression in the TME with a mechanism of action that is differentiated and complementary with T cell focused therapies. KVA12123 may be an effective immunotherapy for many types of cancer including non-small cell lung carcinoma (NSCLC), colorectal, renal cell carcinoma, head and neck, and ovarian cancer.

In February 2024, Kineta announced a significant corporate restructuring to substantially reduce expenses and preserve cash. The restructuring included a significant workforce reduction and the suspension of enrollment of new patients in its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 in patients with advanced solid tumors. At that time, Kineta also announced that it was exploring strategic alternatives to maximize stockholder value.

**IMPORTANT ADDITIONAL INFORMATION REGARDING PROPOSED MERGER WITH KINETA**

In connection with the Merger, TuHURA filed with the U.S. Securities and Exchange Commission (the "SEC") a registration statement on Form S-4, dated February 7, 2025 (the "Registration Statement"), which was declared effective on May 14, 2025 and which contains a joint proxy statement of Kineta and TuHURA and a prospectus of TuHURA (the "Joint Proxy Statement/Prospectus"), and TuHURA and Kineta may file with the SEC other relevant documents regarding the Merger. ***Investors and securityholders of TuHURA and Kineta are urged to read the Joint Proxy Statement/Prospectus and such other materials carefully because they contain important information about TuHURA, Kineta and the Merger. This press release is not a substitute for the definitive Joint Proxy Statement/Prospectus or any other documents that TuHURA may file with the SEC or send to securityholders in connection with the Merger.***

------

---

| | |
|:---|:---|
| ![img118959689_0.jpg](img118959689_0.jpg) | ![img118959689_1.jpg](img118959689_1.jpg) |

---

A definitive copy of the definitive Joint Proxy Statement/Prospectus was mailed to Kineta and TuHURA stockholders beginning May 23, 2025. Investors and stockholders may obtain free copies of the documents filed or that will be filed with the SEC by TuHURA through the website maintained by the SEC at www.sec.gov. The documents filed by TuHURA with the SEC may also be obtained free of charge at TuHURA's website at www.tuhurabio.com or upon written request to: TuHURA, 10500 University Drive, Suite 110, Tampa, Florida 33612.

**NO OFFER OR SOLICITIATION** 

This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Merger and is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy the securities of TuHURA or Kineta, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.

**CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS**

------

---

| | |
|:---|:---|
| ![img118959689_0.jpg](img118959689_0.jpg) | ![img118959689_1.jpg](img118959689_1.jpg) |

---

to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; (x) risks associated with the possible failure to realize certain anticipated benefits of the Merger, including with respect to future financial and operating results; and (xi) other risks and uncertainties described in detail in TuHURA's and Kineta's respective registration statements, reports and other filings with the SEC, which are available on TuHURA's and Kineta's respective websites, and at www.sec.gov.

The forward-looking statements and other information contained in this press release are made as of the date hereof, and TuHURA and Kineta do not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy any securities.

**Investor Contact:**

Monique Kosse<br>Gilmartin Group<br>Monique@GilmartinIR.com

------